Triglycerides play a crucial role in the efficient storage of energy in the body. Mild and moderate hypertriglyceridemia (HTG) is a heterogeneous disorder with significant association with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and peripheral artery disease and represents an important component of the residual ASCVD risk in statin treated patients despite optimal low-density lipoprotein cholesterol reduction. Individuals with severe HTG (>1,000 mg/dL) rarely develop atherosclerosis but have an incremental incidence of acute pancreatitis with significant morbidity and mortality. HTG can occur from a combination of genetic (both mono and polygenic) and environmental factors including poor diet, low physical activity, obesity, medications, and diseases like insulin resistance and other endocrine pathologies. HTG represents a potential target for ASCVD risk and pancreatitis risk reduction, however data on ASCVD reduction by treating HTG is still lacking and HTG-associated acute pancreatitis occurs too rarely to effectively demonstrate treatment benefit. In this review, we address the key aspects of HTG pathophysiology and examine the mechanisms and background of current and emerging therapies in the management of HTG.
14 February 2024 in The Journal of Heart and Lung Transplantation
Aims: Low-density lipoprotein cholesterol (LDL-C) testing and the use of lipid-lowering therapies (LLTs) both reduce risk in patients with atherosclerotic cardiovascular disease (ASCVD). This study aims to assess LDL-C testing and the utilization of LLT in a diverse real-world cohort. Methods and results: This retrospective cohort study assessed 6405 patients who underwent percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), or a peripheral artery disease (PAD) revascularization between 2018 and 2023 at a New York City health system. Patient-level data were extracted from the electronic health record. Multivariable logistic regression analyses were employed to evaluate associations. Overall, 4319 patients (67%) had a follow-up LDL-C test. The median time to follow-up LDL-C testing was 11 months, with 35% having follow-up testing within 6 months. Early LDL-C testing (within 6 months) was associated with higher utilization of high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) monoclonal antibodies (mAbs). At follow-up, 2259 (52%) patients had an LDL-C < 70 mg/dL (1.8 mmol/L). Female sex (odds ratio [OR] 0.70; 95% confidence interval [CI] 0.61, 0.80) and non-Hispanic Black race/ethnicity (OR 0.57; 95% CI 0.49, 0.67) were independently associated with a lower likelihood of achieving a follow-up LDL-C < 70 mg/dL (1.8 mmol/L) after multivariable adjustment. Conclusion: Among patients with ASCVD who underwent revascularization, a large proportion did not have follow-up LDL-C testing, and in those who did, testing was delayed. Only half of patients achieved LDL-C levels below 70 mg/dL (1.8 mmol/L), with female and non-Hispanic Black patients less likely to attain this goal.
12 June 2025 in European Journal of Preventive Cardiology
BACKGROUND: Aortic stenosis (AS) involves calcific and fibrotic degeneration of the valve tissue. The only noninvasive method for evaluating both processes is contrast-enhanced computed tomography angiography. We aimed to explore the differences in aortic valve (AV) tissue composition across sex, race/ethnicity, and AS hemodynamic phenotype in US patients referred for transcatheter AV replacement planning. METHODS: We retrospectively analyzed symptomatic patients with AS who underwent computed tomography angiography for transcatheter AV replacement planning between 2015 and 2022. Using semi-automated software, we quantified the AV tissue composition by fibrotic, calcific, and fibro-calcific volumes, and the fibro-calcific ratio (fibrotic/calcific volume) as a measure of valve phenotype. RESULTS: The study included 651 patients (mean age 84 years; 55% women) with 38% non-Hispanic (NH)-White, 27% Hispanic, and 13% NH-Black. Women had lower fibro-calcific (230 versus 293 mm³/cm²; P <0.001) and calcific volumes (85 versus 149 mm³/cm²; P <0.001), and higher fibro-calcific ratio (1.47 versus 0.83; P <0.001). No differences were observed in the fibrotic volumes ( P =0.805). NH-White women had higher fibro-calcific (256 mm³/cm², P =0.002) and fibrotic volumes (145 mm³/cm²; P <0.001), and fibro-calcific ratio (1.57; P =0.01) compared with Hispanic and NH-Black women. No differences were found among men. High-gradient AS had higher fibro-calcific (295 versus 219 mm 3 /cm 2 ; P <0.001) and calcific volumes (148 versus 88 mm 3 /cm 2 ; P <0.001), and a lower fibro-calcific ratio (0.90 versus 1.45; P <0.001), although no difference in fibrotic volume ( P =0.099) compared with low-gradient AS. CONCLUSIONS: Phenotypic differences in computed tomography angiography valve tissue composition exist in patients with AS referred for transcatheter AV replacement, with women and low-gradient AS showing a proportionally more fibrotic phenotype. NH-White women have the highest fibrotic tissue composition, and no differences are evident among men.